antimalaria

PfDHODH-IN-1, an analogue of the active Leflunomide metabolite, exhibits antimalarial activity.

2,6-Dimethoxyquinone is a plant derived liposuction inducing factor. It has antilipemic, anticancer, antibacterial, antimalarial and anti-inflammatory properties.

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Antimalarial agent 1 is an effective antimalarial agent.

Compound 42 (Compound 2), an antimalarial agent, effectively inhibits Plasmodium falciparum during the asexual blood stages (IC 50 <0.5μM) and gametocytes (IC 50 is 0.14 μM).

Antimalarial agent 43 (compound 16c) is an antimalarial compound that exhibits an IC50 value of 0.0151 μM against the 3D7 strain.

Antimalarial agent 45 (compound 8I) is an antimalarial with activity against Plasmodium parasites, exhibiting an IC50 of 0.21 μM. It is used in the study of malaria.

Antimalarial agent 44 (Compound 3) is an antiparasitic agent effective against malaria. It exhibits good permeability in MDCK-MDR1 cell monolayers and has a high clearance rate in mouse liver microsomes.

Antimalarial agent 46 (Compound 42a) is a compound with antimalarial activity, effective in inhibiting P. falciparum lines.

Antimalarial agent 47 (compound F14) is a chemical compound effective against Plasmodium falciparum, specifically targeting the W2 strain with an IC50 value of 235 nM.

Antimalarial agent 48 (Compound 15a) is a triazine compound with antimalarial activity, showing effectiveness against Plasmodium falciparum K1 and Plasmodium falciparum FCR3 with IC50 values of 280 and 290 nM, respectively. It holds promise for research in the field of anti-infective treatments.

Antimalarial agent 49 is an oral compound with antimalarial properties. It inhibits the growth of Pf3D7 and PfK1 strains, with IC50 values of 0.84 μM and 0.4 μM, respectively. Additionally, it demonstrates the ability to suppress the liver stage development of P. berghei and can be utilized in malaria infection research.

Antimalarial agent 34 is a PfARK1/3 inhibitor, demonstrating potent antiplasmodial activity with an EC50 of 0.16 μM.

Antimalarial agent 35 is a selective inhibitor of FP2. It exhibits antimalarial activity and can act synergistically when used in combination with chloroquine.

Antimalarial agent 41 (Compound 17) exhibits antimalarial activity by inhibiting the malaria parasite Plasmodium falciparum, with IC50 values of 40 nM for NF54 strain and 76 nM for K1 strain. This compound acts as an inhibitor of P. falciparum phosphatidylinositol-4-kinase β (PfPI4K) and hERG channels, with IC50 values of 53 nM and 3 μM, respectively. Additionally, Antimalarial agent 41 shows cytotoxicity against CHO cells, with an IC50 of 34 μM. It can improve malaria infections and demonstrates favorable pharmacokinetic properties in mouse models.

Antimalarial agent 51 (Compound 2) is an orally active antimalarial compound that inhibits the growth of Plasmodium parasites by blocking nutrient uptake through the Plasmodium Surface Anion Channel (PSAC). This agent significantly restricts parasite growth under nutrient-limiting conditions and demonstrates enhanced effectiveness in combination with the residual transport inhibitor PRT-2. It is suitable for research on PSAC-targeting malaria.

Antimalarial agent 50 is a compound that acts against malaria-causing parasites. In mouse models, it is effective against Plasmodium berghei-induced malaria infections. Antimalarial agent 50 modulates oxidative stress and significantly reduces inflammatory cytokine levels. This compound is applicable in malaria research.

Antimalarial agent 52 is an orally effective synthetic inhibitor of malaria pigment (β-hematin), with an IC50 of 6.6 μM. In vitro, it exhibits antimalarial activity against Plasmodium falciparum strains Pf3D7 and PfDd2, and Plasmodium knowlesi, with IC50 values of 6.1, 6.4, and 3.3 nM, respectively. It remains potent against multidrug-resistant strains and demonstrates significant efficacy in a Plasmodium berghei (P. berghei) mouse model.

Antimalarial agent 54 (Compound 23) is a potent antimalarial compound that primarily targets the late-stage trophozoites of the malaria parasite. It inhibits the formation of hemozoin within the parasite, resulting in the accumulation of free hemoglobin. The IC50 values for Plasmodium falciparum strains NF54 and Dd2 are 0.14 μM and 0.19 μM, respectively. Antimalarial agent 54 is applicable in malaria research.

Antimalarial agent 3, an antimalarial agent, exhibits potent activity against Plasmodium with an IC50 of 0.035 μM. Furthermore, it demonstrates an exceptionally high selectivity index in relation to mammalian cells.

Antimalarial agent 11 (compound 1), a spirocyclic chromane, is a potent antimalarial agent effective against D6 (EC50: 1.48 μM) and ARC08-022 (EC50: 1.81 μM).

Antimalarial agent 7 is a potent and effective inhibitor of PfATP4, showing potential for studying human Plasmodium falciparum.